2017
DOI: 10.5812/ircmj.13529
|View full text |Cite
|
Sign up to set email alerts
|

Camel Milk with Pegylated Interferon Alfa-2a and Ribavirin for Treatment-Naive Chronic Hepatitis C Genotype 2/ 3: An Open-Label, Randomized Controlled Trial

Abstract: Background: Chronic hepatitis C is one of the most important causes of cirrhosis and hepatocellular carcinoma (HCC). Camel milk (CM) is a new candidate therapy for chronic hepatitis C (CHC).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 23 publications
(25 reference statements)
0
0
0
Order By: Relevance